Home › Lung Diseases › Minnesota
Lung Diseases clinical trials in Minnesota
7 studies for Lung Diseases are looking for participants at sites in Minnesota.
Cities in Minnesota
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Headlands Research-Twin Cities, Maplewood
RecruitingPhase 2
Ages 40 to 75 · All sexes · Updated Sep 25, 2026 · NCT07759245A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- HealthPartners Cancer Research Center, Saint Paul
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- Research Site, Saint Paul
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05624450A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 108, Rochester
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Aug 11, 2026 · NCT07555483Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Minnesota, Minneapolis
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis
Recruiting
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT02984761Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Sep 29, 2025 · NCT04555161From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.